Drug Profile
Annamycin liposomal - Moleculin Biotech
Alternative Names: Annamycin-LF; Annamycin-liposomal; L-ANNA; L-annamycin; Liposomal annamycin; S-ANNALatest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Aronex Pharmaceuticals; Callisto Pharmaceuticals; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Soft tissue sarcoma
- Phase I/II Acute myeloid leukaemia
- Preclinical Colorectal cancer; Liver cancer; Pancreatic cancer; Solid tumours
- Discontinued Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Triple negative breast cancer
Most Recent Events
- 18 Apr 2024 Annamycin liposomal - Moleculin Biotech receives Orphan Drug status for Acute myeloid leukaemia in Europe
- 11 Apr 2024 Pharmacodynamics data from a preclinical study in Soft tissue sarcoma released by Moleculin Biotech
- 27 Mar 2024 Moleculin Biotech receives patent issue notification for Annamycin from USPTO